Lawrence M. Blatt's most recent trade in Aligos Therapeutics Inc was a trade of 140,103 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aligos Therapeutics Inc | Lawrence M. Blatt | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 140,103 | 140,103 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Lawrence M. Blatt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2024 | 33,920 | 33,920 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Lawrence M. Blatt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 965,435 | 965,435 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Blatt Lawrence M. | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 450,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Blatt Lawrence M. | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 323,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Lawrence M. Blatt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 230,999 | 230,999 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | M. Blatt Lawrence | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 132,352 | 132,352 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Lawrence M. Blatt | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 80,850 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Blatt Lawrence M. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 57,749 | 57,749 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 242,500 | 242,500 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 161,700 | 161,700 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 323,400 | 323,400 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 80,850 | 80,850 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 122,601 | 0 | - | - | Series A Preferred Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 122,601 | 122,601 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 50,712 | 0 | - | - | Series B-1 Preferred Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 50,712 | 91,728 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 41,016 | 0 | - | - | Series A Preferred Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 41,016 | 41,016 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 21,695 | 113,423 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 21,695 | 0 | - | - | Series B-2 Preferred Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 13,671 | 0 | - | - | Series A Preferred Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 13,671 | 0 | - | - | Series A Preferred Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 13,671 | 13,671 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 13,671 | 13,671 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 3,394 | 0 | - | - | Series B-1 Preferred Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 3,394 | 0 | - | - | Series B-1 Preferred Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 3,394 | 17,065 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 3,394 | 17,065 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 1,452 | 18,517 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 1,452 | 18,517 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 1,452 | 0 | - | - | Series B-2 Preferred Stock | ||
| Aligos Therapeutics Inc | Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 1,452 | 0 | - | - | Series B-2 Preferred Stock |